Transcriptomics,Genomics

Dataset Information

41

Gene expression analysis of imatinib-resistant GIST


ABSTRACT: To reveal mechanisms for acquired imatinib resistance in gastrointestinal stromal tumor (GIST), we have analyzed several cell lines with resistance to imatinib. Overall design: The parental cell line, T1, was cultured exposed to imatinib, doses of which were increased in a stepwise manner where we selected survived cells until normal cell growth resumed. Thus, we independently established imatinib-resistant GIST cell lines, which exhibited more than 500 times IC50 values (over 10 μM) for imatinib compared to the parental line. R2, RA2, R8, and R9 are fully resistant cell lines. T117 was exposed only for 7 weeks.

INSTRUMENT(S): Agilent-039494 SurePrint G3 Human GE v2 8x60K Microarray 039381 (Feature Number version)

SUBMITTER: Momoko NAGAI 

PROVIDER: GSE69465 | GEO | 2016-12-27

SECONDARY ACCESSION(S): PRJNA285670

REPOSITORIES: GEO

altmetric image

Publications


Gastrointestinal stromal tumors represent the most common mesenchymal tumor of the digestive tract, driven by gain-of-function mutations in KIT. Despite its proven benefits, half of the patients treated with imatinib show disease progression within 2 years due to secondary resistance mutations in KIT. It remains unclear how the genomic and transcriptomic features change during the acquisition of imatinib resistance. Here, we performed exome sequencing and microarray transcription analysis for fo  ...[more]

Similar Datasets

2013-01-01 | S-EPMC3825279 | BioStudies
1000-01-01 | S-EPMC3587280 | BioStudies
2011-01-01 | S-EPMC3111164 | BioStudies
2012-01-01 | S-EPMC3992119 | BioStudies
2019-01-01 | S-EPMC6815454 | BioStudies
2012-01-01 | S-EPMC3366284 | BioStudies
2016-01-01 | S-EPMC4978997 | BioStudies
2017-01-01 | S-EPMC5203981 | BioStudies
2017-01-01 | S-EPMC5354847 | BioStudies
1000-01-01 | S-EPMC6125455 | BioStudies